| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $0 | — | — |
| R&D Expense | $4.2M | +8.9% | -3.3% |
| SG&A Expense | $2.9M | -4.5% | -3.4% |
| Operating Income | -$7.1M | -3.1% | +3.4% |
| Net Income | -$6.8M | -2.9% | +4.5% |
| EPS (Basic) | -$0.06 | +14.3% | +40.0% |
| EPS (Diluted) | -$0.06 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $44.3M | +75.2% | +110.7% |
| Current Assets | $49.1M | +66.6% | +104.1% |
| Total Assets | $51.6M | +59.6% | +94.5% |
| Current Liabilities | $5.9M | -1.2% | -44.2% |
| Total Liabilities | $5.9M | -3.8% | -44.2% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$23.5M | — | — |
| Financing Cash Flow | $53.9M | — | — |
| +40.0% |
| $45.6M |
| +74.5% |
| +187.1% |